Silicon Valley Capital Partners’s AstraZeneca AZN Stock Holding History

Silicon Valley Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-280	Closed	-$41.3K	–	308
2025 Q1	$41.3K	Buy	280 +4	+1%	+$579	0.01%	143
2024 Q4	$36.2K	Hold	276	–	–	﹤0.01%	160
2024 Q3	$43K	Buy	276 +1	+0.4%	+$161	0.01%	141
2024 Q2	$42.8K	Hold	275	–	–	0.01%	136
2024 Q1	$37.2K	Buy	275 +4	+1%	+$530	0.01%	135
2023 Q4	$36.4K	Sell	271 -30	-10%	-$3.9K	0.01%	120
2023 Q3	$40.7K	Buy	301 +2	+0.7%	+$273	0.01%	104
2023 Q2	$42.7K	Buy	299 +269	+897%	+$39.6K	0.01%	104
2023 Q1	$4.13K	Hold	30	–	–	﹤0.01%	200
2022 Q4	$3.98K	Buy	+30	New	+$3.76K	﹤0.01%	165

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Silicon Valley Capital Partners's AZN Position: Q2 2025 in Review

Silicon Valley Capital Partners sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 280 shares — an estimated $41.3K sold.

Silicon Valley Capital Partners first reported a position in AZN in Q4 2022 and held it in 10 quarters. The position peaked at $43K in Q3 2024. 1,223 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Silicon Valley Capital Partners reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Silicon Valley Capital Partners sold 280 AstraZeneca shares in Q2 2025, an estimated $41.3K.
Silicon Valley Capital Partners first reported a position in AstraZeneca in Q4 2022 and held it in 10 quarters.
Silicon Valley Capital Partners's AstraZeneca position peaked at $43K in Q3 2024.
1,223 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Silicon Valley Capital Partners's 13F filing for Q2 2025, filed 11 Sep 2025.